CANOVA study was aimed at providing real-world evidence of the effectiveness of biologics in Italian patients with moderate-severe psoriasis. It was an observational, retro-prospective cohort study conducted in 17 Italian dermatology clinics. Adult patients with moderate-severe plaque psoriasis, who started a biologic treatment between 24 months and 24 weeks before enrolment, were included. With a follow-up visit at 6 months after enrolment, each patient had at least12 months of observation. The primary objective was to describe the clinical response rates (PASI 75) after 16/24/52 weeks from biologic treatment start. Secondary outcomes were sustained response, quality of life and treatment satisfaction. Of the 669 eligible patients (64% males), 52% were naïve to biologics, though a mean duration of psoriasis since first diagnosis of 18.6 years (SD 13.2). The most frequently prescribed biologics were secukinumab (41%), ustekinumab (25%), TNF-inhibitors (22%) and ixekizumab (12%). PASI 75 was achieved by 86% of patients (95% CI: 82%-89%) at 16 weeks, 90% (87%-93%) at 24 weeks, and 91% (89%-94%) at 52 weeks. Patients achieving PASI 90 and PASI 100 at 52 weeks were 75% (71%-79%) and 53% (49%-57%), respectively. Sustained PASI 75 response after 1 year from treatment start was achieved by 78% (74%-82%) of patients. Mean DLQI total score was 2.3 (SD 3.9) at enrollment and decreased at the final visit to 1.8 (3.6). A high level of treatment satisfaction was expressed by patients over the study period. This large real-world study confirms in the clinical practice the good effectiveness and acceptability of biologics in psoriasis patients. This article is protected by copyright. All rights reserved.

Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study / Colombo, Delia; Bianchi, Luca; Fabbrocini, Gabriella; Corrao, Salvatore; Offidani, Annamaria; Stingeni, Luca; Costanzo, Antonio; Pellacani, Giovanni; Peris, Ketty; Bardazzi, Federico; Argenziano, Giuseppe; Ruffolo, Silvana; Dapavo, Paolo; Carrera, Carlo; Fargnoli, Maria Concetta; Parodi, Aurora; Romanelli, Marco; Malagoli, Piergiorgio; Talamonti, Marina; Megna, Matteo; Raspanti, Massimo; Paolinelli, Matteo; Hansel, Katharina; Narcisi, Alessandra; Conti, Andrea; De Simone, Clara; Chessa, Marco Adriano; De Rosa, Alina; Provenzano, Eugenio; Ortoncelli, Michela; Moltrasio, Chiara; Fidanza, Rosaria; Burlando, Martina; Tonini, Annalisa; Gaiani, Francesca Maria; Simoni, Lucia; Ori, Alessandra; Fiocchi, Martina; Zagni, Emanuela. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - (2021), p. e15166. [10.1111/dth.15166]

Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study

Fabbrocini, Gabriella;Megna, Matteo;
2021

Abstract

CANOVA study was aimed at providing real-world evidence of the effectiveness of biologics in Italian patients with moderate-severe psoriasis. It was an observational, retro-prospective cohort study conducted in 17 Italian dermatology clinics. Adult patients with moderate-severe plaque psoriasis, who started a biologic treatment between 24 months and 24 weeks before enrolment, were included. With a follow-up visit at 6 months after enrolment, each patient had at least12 months of observation. The primary objective was to describe the clinical response rates (PASI 75) after 16/24/52 weeks from biologic treatment start. Secondary outcomes were sustained response, quality of life and treatment satisfaction. Of the 669 eligible patients (64% males), 52% were naïve to biologics, though a mean duration of psoriasis since first diagnosis of 18.6 years (SD 13.2). The most frequently prescribed biologics were secukinumab (41%), ustekinumab (25%), TNF-inhibitors (22%) and ixekizumab (12%). PASI 75 was achieved by 86% of patients (95% CI: 82%-89%) at 16 weeks, 90% (87%-93%) at 24 weeks, and 91% (89%-94%) at 52 weeks. Patients achieving PASI 90 and PASI 100 at 52 weeks were 75% (71%-79%) and 53% (49%-57%), respectively. Sustained PASI 75 response after 1 year from treatment start was achieved by 78% (74%-82%) of patients. Mean DLQI total score was 2.3 (SD 3.9) at enrollment and decreased at the final visit to 1.8 (3.6). A high level of treatment satisfaction was expressed by patients over the study period. This large real-world study confirms in the clinical practice the good effectiveness and acceptability of biologics in psoriasis patients. This article is protected by copyright. All rights reserved.
2021
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study / Colombo, Delia; Bianchi, Luca; Fabbrocini, Gabriella; Corrao, Salvatore; Offidani, Annamaria; Stingeni, Luca; Costanzo, Antonio; Pellacani, Giovanni; Peris, Ketty; Bardazzi, Federico; Argenziano, Giuseppe; Ruffolo, Silvana; Dapavo, Paolo; Carrera, Carlo; Fargnoli, Maria Concetta; Parodi, Aurora; Romanelli, Marco; Malagoli, Piergiorgio; Talamonti, Marina; Megna, Matteo; Raspanti, Massimo; Paolinelli, Matteo; Hansel, Katharina; Narcisi, Alessandra; Conti, Andrea; De Simone, Clara; Chessa, Marco Adriano; De Rosa, Alina; Provenzano, Eugenio; Ortoncelli, Michela; Moltrasio, Chiara; Fidanza, Rosaria; Burlando, Martina; Tonini, Annalisa; Gaiani, Francesca Maria; Simoni, Lucia; Ori, Alessandra; Fiocchi, Martina; Zagni, Emanuela. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - (2021), p. e15166. [10.1111/dth.15166]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/861664
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 15
social impact